Lightstone Ventures is a venture capital firm that describes itself as partners, collaborators, and mentors.

Lightstone Ventures

Lightstone Ventures is a global venture capital fund dedicated to translating novel scientific breakthroughs into clinically and commercially meaningful therapies. We invest in biotech and medtech companies pioneering the big ideas poised to transform patient outcomes. We were founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary bring innovative therapeutics and technologies to the people who need them most.    

Our investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. We have offices in Boston, Mass., Menlo Park, Calif., and Dublin, Ireland.

For more information, visit www.lightstonevc.com.

Nimbus Apollo

Ra Pharmaceuticals

ALX Oncology

Vigil Neuroscience

Gemini Therapeutics

Nimbus Therapeutics

Bold Penguin

Astria Therapeutics

Cyteir Therapeutics

Disarm Therapeutics

Flex Pharma

Claret Medical

Lightstone portfolio company Atsena Therapeutics recently welcomed Joe Zakrzewski as Board Chair. His deep industry expertise in therapeutic development and commercialization and leadership across multiple biotechnology and pharmaceutical companies will be a valuable addition to Atsena as the company continues to advance their best-in-class treatments for inherited retinal diseases in the clinic. Learn more: https://bit.ly/4bENzBH

Congratulations to Amber Therapeutics on the closing of their successful $100 million Series A financing. Lightstone is proud to be a fund partner and we look forward to updates as the company advances Amber-UI, their adaptive neuromodulation therapy for mixed urinary incontinence, towards US FDA approval. Full press release: https://bit.ly/3VzIHsD

Lightstone portfolio company Cala Health recently announced the Cala TAPS therapy is now covered by Medicare for essential tremor patients. Great news and great for patients! Full press release: https://prn.to/45rZHoc

Congratulations to Alchemab Therapeutics Ltd, a Lightstone portfolio company, on their grant by the The Michael J. Fox Foundation for Parkinson's Research to support their #Parkinson’s disease (PD) program, currently researching the therapeutic effects of its resilient patient-derived antibody in PD. Read here: https://prn.to/4efl0xd

We’re looking forward to Nimbus Therapeutics’ #ASCO24 presentation of new positive data from their Phase 1/2 clinical trial of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor in development for the treatment of advanced #solidtumors. More about the results here: https://bit.ly/3Kere2j

Lightstone portfolio company Tizona Therapeutics, Inc. is presenting first-in-human Phase 1b clinical data of TTX-080, their antibody targeting HLA-G, in patients with metastatic colorectal cancer and locally advanced/metastatic head and neck squamous cell carcinoma at #ASCO24: https://bit.ly/3Kes4ft

LIGH

COM:LIGHTSTONEVC

Lightstone Ventures